Maze Therapeutics stock

Maze Therapeutics Stock


Looking to sell Maze Therapeutics stock or options?

Contact us
Founded: 2018Funding to Date: $384M
Visit website

Maze Therapeutics has designed a biotechnology platform that is centered on transforming genetic insights into innovative medicines. The platform integrates comprehensive human genetic data analysis, functional genomics, and a range of drug discovery techniques to identify modifier genes that offer protection. This facilitates a more profound understanding of target biology and how these targets can be effectively addressed with drug treatments. This enables pharmaceutical companies to create novel therapeutic options.

Investors include:
Andreessen Horowitz logo
Further Key Investors:

Driehaus Capital Management, Moore Strategic Ventures, Timefolio Capital, General Catalyst, Matrix Capital Management, Alexandria Venture Investments, ARCH Venture Partners, Third Rock Ventures, Casdin Capital, City Hill Ventures, GV, The Sobrato Organization, Terra Magnum Capital Partners, Moore Capital Management, Woodline Partners, Paratus Investment, Foresite Capital.